



Company Announcement no. 4/2009

To: OMX Nordic Exchange

Hørsholm, Denmark, March 6, 2009

LifeCycle Pharma A/S – Report Pursuant to the Danish Securities Trading Act, Section 28(a)

Hørsholm, Denmark, March 6, 2009; Pursuant to the Danish Securities Trading Act, Section 28(a), LifeCycle Pharma A/S (OMX: LCP) is required on a daily basis, to make public transactions in LifeCycle Pharma shares and related securities by persons discharging managerial responsibilities and persons / companies closely associated with these.

| | |
|-----------------------------|-------------------------------------|
| Name | Jim New |
| Reason for reporting | President & CEO |
| Issuer and ID code/ISIN | LifeCycle Pharma A/S / DK0060048148 |
| Type of transaction | Purchase of shares |
| Date of transaction | March 6, 2009 |
| Relevant market | NASDAQ OMX Copenhagen |
| Number of traded securities | 18,181 |
| Market value | DKK 196,977 |

For more information, please contact:

LifeCycle Pharma A/S
Peter Schøtt Knudsen
Head of Investor Relations
Phone: + 45 2055 3817
Email: PSK@lcpharma.com

About LifeCycle Pharma A/S (LCP)

Based in Hørsholm, Denmark, with an office in New York, LCP is an emerging specialty pharmaceutical company. Clinical development is the core of LCP's effort to develop a product portfolio which includes products for immunosuppression, specifically organ transplantation, and products to combat certain cardiovascular diseases. As a fully integrated company, LCP adapts new technologies on a fast commercial timetable. LCP's unique, patented delivery technology, MeltDose[®], can improve absorption and bioavailability – at low-scale up costs – not only for a broad spectrum of drugs already on the market but also for new chemical entities. LCP has a cholesterol-lowering product, Fenoglide[™], currently on the U.S. market and a diversified near- and medium-term pipeline with four product candidates in clinical trials and a number of projects one in preclinical development. LCP is listed on NASDAQ OMX Copenhagen under the trading symbol (OMX: LCP).

For further information, please visit www.lcpharma.com.

LIFECYCLE PHARMA A/S
KOGLE ALLÉ 4
DK-2970 HØRSHOLM
WWW.LIFECYCLEPHARMA.COM
TEL. +45 7033 3300
FAX +45 3613 0319
CVR. 26 52 77 67
INFO@LCPHARMA.COM

page 1 of 1